entertainment -WSS

entertainment

author：entertainment 2025-08-23 06:50:58 - browse：25

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Amylyx ALS drug failure raises questions and concerns

WSS

Prosthetic arm enables patients to feel the objects they grip

Insmed lung disease drug hits target in key Phase 3 trial

iTeos Therapeutics debuts first data on TIGIT

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Air quality improving but still lags in Black, Hispanic communities

NEJM study link tiny plastics in blood vessels to heart problems

Wikipedia

entertainment

explore

After affirmative action ruling, medical educators look to 'holistic review'

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Jerome Adams on the need for new antivirals for Covid

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Trump demands the U.S. pay no more for drugs than other countries … again

What will save rural psychiatry services? Higher Medicaid payments

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Moonlake's readout produced a cash windfall. Risks remain

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

focus

What it’s like to watch children die of measles

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

What it’s like to watch children die of measles

David Sabatini, ex

NEJM study link tiny plastics in blood vessels to heart problems

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Wikipedia

focus

focus

entertainment